Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. (Q43032258)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Maurizio Soresi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Vito Franco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Francesca Rappa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

S Tripi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A Alessandri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

O Vuturo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

G Montalto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

1 reference

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

1119-1125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17032413%20AND%20SRC:MED&resulttype=core&format=json

Hepatic steatosis: innocent bystander or guilty party?

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Interaction of non-alcoholic fatty liver disease with other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01347.X